五度妙笔
API商城
数据库药明康德瑞士早餐会：新药研发的“协同加速度”｜Bilingual
当今医疗健康领域面临的核心挑战之一，并非科学创新的匮乏。从许多方面来看，情况恰恰相反。生物医药科学技术正以前所未有的速度向前推进，新的治疗模式正打开曾经遥不可及的可能性之门，世界各地的研究人员不断拓展着创新科学造福病患的边界。
然而，更严峻的挑战在于，如何将这些进步，以患者急需的速度和质量，转化为切实可及的治疗方案。
正是这个命题，贯穿了在巴塞尔举行的WuXi Executive Breakfast的整场讨论。该活动在瑞士生物技术日期间举办，吸引了来自生物技术、制药、风险投资以及更广泛的医疗健康生态系统的行业领袖。
讨论中，演讲者从不同的视角，回归到一个相似的结论：仅凭科学创新已不足以应对当下挑战。产业进步越来越取决于药物发现、开发、生产以及全球专业能力能否形成一体化系统，并实现高效协同。
这场讨论，从多个维度呼应了今年瑞士生物技术日主题所倡导的精神——国际合作的力量。
▲从左至右依次为：药明康德副总裁Vikalp Mohan先生、副总裁蔡辉博士、副总裁Dave Madge博士、药明康德旗下Crelux公司负责人Thomas Meins博士
速度至关重要：缩短患者等待的时间
对于新兴的生物技术公司而言，时间是最稀缺的资源之一。
FoRx Therapeutics最近刚宣布完成5000万美元的A轮融资。其首席科学官Frank Zenke博士分享了该公司如何在约18个月内，将一款DNA修复小分子抑制剂从分析方法开发推进至IND获批。他表示：“在药明康德的帮助下，我们成功开发了临床前检测方法，完成了IND准备工作，并推进了CMC相关工作。”在他看来，科学之外，项目能否快速推进，取决于专业知识和执行能力能否围绕共同目标有效协同。
与此同时，创新本身的复杂度也在持续攀升。
Debiopharm Research & Manufacturing的首席执行官Cédric Sager博士指出，抗体偶联药物（ADC）和放射性配体疗法等新兴治疗模式正在重塑行业的开发需求。这些疗法越来越依赖于高度专业化的能力，涵盖连接子化学、多肽技术、先进生产以及协调的供应体系。“我们在某些领域是专家，”他说，“但在其他领域，我们需要伙伴与我们并肩前行。”
科学研究越是迈向新的前沿，研发生态系统就越必须随之演进。
协作：决定创新速度的关键变量
拜耳制药瑞士区负责人Thorsten Hein先生强调了在产业链上下游，以及不同国家和地区之间建立更牢固桥梁的重要性，以推动创新更高效、更可靠地造福患者。
他指出，患者需求和医疗创新本身都具有全球性，关键在于搭建连接欧洲、亚洲和北美之间的桥梁，使合作能够更紧密、更高效地展开。
这种互联互通的精神，也是瑞士生物技术日的核心氛围。瑞士生物技术协会首席执行官Michael Altorfer博士强调，构建一个能够让全球生物科技行业自然建立信任与协作的生态，至关重要。他指出，像瑞士生物技术日这样汇聚3600多位参会者，其中50%来自瑞士以外地区的大会，恰恰为创新者、科学家、投资者和合作伙伴提供了宝贵的连接机会，最终有助于加速将治疗进展带给患者。
在现代药物研发中，协作已不再仅仅是创新的辅助手段。它正日益成为使创新得以实现的基础设施。
一体化：正在成为加速创新的重要推动力
随着研发项目日趋复杂——涵盖下一代小分子、多肽、寡核苷酸、偶联物以及其他新兴治疗模式——讨论自然转向了一体化执行的重要性。
在此背景下，药明康德的一体化、端到端的CRDMO平台被多次提及。该平台打通了从药物发现、开发至商业化生产的全链条能力，可有效解决传统研发中因环节分散、割裂而导致的低效问题，加速客户的新药项目从构想到落地的转化进程。就在活动举办前三天，美国FDA批准了首款异双功能性蛋白降解剂，为靶向蛋白降解领域带来重要里程碑。 药明康德依托CRDMO一体化平台整合化学、生物学和测试等能力，助力临床前候选化合物在13个月内的快速推进和交付，而行业常规周期约为24个月。药明康德还为这一项目提供了从快速开发、放大生产到用于临床试验的GMP物料生产的端到端支持。
讨论也进一步诠释了药明康德持续拓展全球能力和区域布局的意义。为满足全球客户对研发效率、产能弹性和本地化支持的需求，药明康德持续加快能力与产能建设。在欧洲，药明康德位于德国慕尼黑和瑞士库威的基地持续为欧洲及全球客户提供从早期研发到高质量制剂生产的支持。去年，药明康德宣布将在慕尼黑设立欧洲总部，以更好地支持欧洲客户。更贴近欧洲、北美和亚洲的合作伙伴，意味着更及时的沟通、更顺畅的协作和更高效的项目推进，从而为全球创新提供更坚实的支持。
一个愈发清晰的趋势
瑞士生物技术日作为极具代表性且高度国际化的活动，反映了一个日益增长的共识：从科学发现到造福患者的连接路径，正变得更加互联、多学科和全球化。医疗健康的进步正越来越成为一项集体事业，需要集体的努力和协同。
而这，或许正是这个早晨最值得铭记的一课：当今药物研发领域最重要的生态创新，或许是整个行业如何更有效地携手合作——将有望改变生命的科学成果，以更高效、更可靠的方式，带给全球患者。
The Most Important Innovation in Drug R&D May Be How the Industry Works Together
Reflections from the WuXi Executive Breakfast at Swiss Biotech Day
One of the defining challenges in healthcare today is not a lack of scientific ideas. In many ways, the opposite is true. The greater challenge now is translating those advances into therapies with the speed and quality patients urgently need.
That theme shaped the discussions at the WuXi Executive Breakfast in Basel, held alongside Swiss Biotech Day and attended by nearly 100 leaders from biotech, pharma, venture capital, and the broader healthcare ecosystem.
Throughout the morning, speakers returned — often from very different perspectives — to a remarkably similar conclusion: scientific innovation alone is no longer enough. Increasingly, progress depends on how effectively discovery, development, manufacturing, and global expertise can work together as an integrated system.
In many ways, the conversation reflected the broader spirit of this year’s Swiss Biotech Day theme — The Power of International Collaboration.
▲From left to right: Mr. Vikalp Mohan, Vice President at WuXi Chemistry; Dr. Hui Cai, Vice President, WuXi AppTec; Dr. Dave Madge, Vice President at WuXi Biology; Dr. Thomas Meins, Managing Director at Crelux, a WuXi AppTec company
Speed Matters Because Patients Are Waiting
For emerging biotech companies, time remains one of the most precious resources.
Dr. Frank Zenke, CSO of FoRx Therapeutics based in Switzerland, which recently announced a $50 million Series A financing, shared how the company advanced a small molecule inhibitor from assay development into an IND-approved program and Phase 1 trial within roughly 18 months. “We successfully developed a preclinical assay, prepared the IND, and worked on the CMC with the help of WuXi AppTec,” he said. For him, the ability to move quickly depends on how effectively expertise and execution capabilities can align around a common goal.
Innovation itself is also becoming more sophisticated.
Dr. Cédric Sager, CEO of Debiopharm Research & Manufacturing, described how emerging modalities such as ADCs and radioligand therapies are reshaping development requirements across the industry. These therapies increasingly rely on highly specialized capabilities spanning linker chemistry, peptide technologies, advanced manufacturing, and coordinated supply systems.
“We are experts in some areas,” he noted, “but we need others to help us move forward.” As science advances into new frontiers, development ecosystems must evolve alongside it.
Collaboration Is Becoming Infrastructure
Mr. Thorsten Hein, Country Division Head of Bayer Pharma Switzerland, emphasized the importance of building stronger bridges across the upstream and downstream parts of the industry value chain, as well as across countries and regions, to help innovation reach patients efficiently and reliably.
With both patient needs and healthcare innovation becoming inherently global, he said, “It’s about building bridges between Europe, Asia, and the U.S., so we can work together more closely and effectively.”
That spirit of connectivity was central to the atmosphere of Swiss Biotech Day itself.
Dr. Michael Altorfer, CEO of the Swiss Biotech Association, reflected on the importance of creating environments where trust and relationships can develop naturally across the global biotech community. “Our relationship with WuXi dates back many, many years,” he said. Conferences like Swiss Biotech Day with 3600 delegates and 50% from outside Switzerland, he noted, help innovators, scientists, investors, and partners connect in ways that can ultimately accelerate progress for patients.
In modern drug development, collaboration is no longer simply supportive to innovation. Increasingly, it is becoming part of the infrastructure that makes innovation possible.
Integration as an Enabler of Innovation
As scientific programs become more complex — spanning next-generation small molecules, peptides, oligonucleotides, conjugates, and other emerging modalities — many conversations naturally turned toward the importance of integrated execution.
Within that context, WuXi AppTec’s integrated CRDMO platform was discussed as one approach designed to help innovators move more seamlessly across traditionally fragmented stages of development by connecting discovery, development, and manufacturing through coordinated teams and technology platforms.
The discussion also further underscored the significance of WuXi AppTec’s continued expansion of its global capabilities and regional footprint. To meet global customers’ needs for R&D efficiency, capacity flexibility, and localized support, WuXi AppTec is accelerating the build-out of its capabilities and capacity.
In Europe, WuXi AppTec's sites in Munich, Germany and in Couvet, Switzerland continue to support customers in Europe and around the world, from early-stage R&D to high-quality drug product manufacturing.
Last year, WuXi AppTec announced plans to establish its European headquarters in Munich to better support customers across Europe. Being closer to partners in Europe, North America, and Asia means more timely communication, smoother collaboration, and more efficient project execution, providing stronger support for global innovation.
What the Breakfast Ultimately Reflected
By the end of the session, one thing had become increasingly clear: the future of drug development will not be defined solely by scientific breakthroughs themselves, but by how effectively the global R&D ecosystem can coordinate around those breakthroughs.
Swiss Biotech Day’s largest and most international gathering to date reflected the growing recognition that healthcare progress is increasingly a collective effort.
And perhaps that was the most important insight from the morning:
The most important innovation in drug R&D today may be how effectively the industry learns to work together to bring innovation to patients around the world.
版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
分享，点赞，在看，聚焦全球生物医药健康创新
